Santhera to Raise Capital Through Sale of Newly Created Shares

ID: 1376028
recent pressrelease next pressrelease

(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera to Raise Capital Through Sale of Newly Created Shares
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

Liestal, Switzerland, July 31, 2015 - Santhera Pharmaceuticals (SIX: SANN)
announces the intent to sell up to 300,000 registered shares of newly created
treasury shares (representing 6.03% of the company''s total outstanding share
capital). The proceeds will be used to finance the commercial launch of Raxone®
in Leber''s Hereditary Optic Neuropathy (LHON) in Europe.

The shares available-for-sale with a par value of CHF 1.00 will be issued from
the Company''s conditional capital. The Company has mandated Kepler Chevreux as
independent broker to sell the shares to institutional investors and in the open
market starting from August 3, 2015.

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera develops Raxone(®)/Catena(®) as treatment for patients with Leber''s
Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and
primary progressive Multiple Sclerosis (ppMS) and omigapil for Congenital
Muscular Dystrophy (CMD), all areas of high unmet medical need. In June 2015,
the Committee for Medicinal Products for Human Use (CHMP) recommended granting a
marketing authorization in Europe for Raxone(®) for the treatment of LHON. For
further information, please visit the Company''s website

Raxone(®) and Catena(®) are trademarks of Santhera Pharmaceuticals.

For further information, contact:
Thomas Meier, PhD, Chief Executive Officer
Phone +41 61 906 89 64


Christoph Rentsch, Chief Financial Officer
Phone +41 61 906 89 65

US investor contact:
Hans Vitzthum, LifeSci Advisors, LLC
Phone +1 857 272 617

US Public Relations contact:
Deanne Eagle, Planet Communications
Phone +1 917 837 5866

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.

# # #

News release Financing:

This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 07/31/2015 - 01:00
Language: English
News-ID 1376028
Character count: 0
Firma: Santhera Pharmaceuticals Holding AG
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Liestal


Number of hits: 275


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 43

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.